A trial comparing olaparib with enzalutamide or abiraterone for men with prostate cancer (PROfound)

This trial compared olaparib with enzalutamide or abiraterone for men with prostate cancer that had spread to other parts of the body.

It was for men who’d:

• had surgery to remove the testicles (orchidectomy) or were having treatment with hormone therapy

• had changes in genes called homologous recombination repair (HRR)

This trial was open for people to join between May and September 2018. The results were published in a journal in 2020 and on the pharmacy company’s website in 2021.